Novel SPTBN2 gene mutation and first intragenic deletion in early onset spinocerebellar ataxia type 5

Romina Romaniello1, Andrea Citterio2, Elena Panzeri2, Filippo Arrigoni3,a, Marta De Rinaldis4, Antonio Trabacca4 & Maria Teresa Bassi2

1Neuropsychiatry and Neurorehabilitation Unit, Scientific Institute, IRCCS Eugenio Medea, Bossio Parini, Italy
2Laboratory of Molecular Biology, Scientific Institute, IRCCS Eugenio Medea, Bossio Parini, Italy
3Neuroimaging Lab, Scientific Institute, IRCCS Eugenio Medea, Bossio Parini, Italy
4Unit for Severe Disabilities in Developmental Age and Young Adults, Scientific Institute, IRCCS E. Medea, Brindisi, Italy

Correspondence
Romina Romaniello, Neuropsychiatry and Neurorehabilitation Unit, IRCCS Eugenio Medea, Via D. L. Monza 20, 23842, Bossio Parini, Lecco, Italy. Tel: 0039 031877111; Fax: 0039 031877499; E-mail: romina.romaniello@lanostrafamiglia.it

Present address
aRadiology Unit, Ospedale Fatebenefratelli e Oftalmico, Milan, Italy

Abstract
In the present study, we describe two novel cases of SCA5 with early onset. The first one, carrying a novel heterozygous de novo missense mutation in SPTBN2 gene, showed a striking very severe cerebellar atrophy and reduction of volume of the pons at a very young age (16 months). The latter, carrying the first de novo intragenic deletion so far reported in SPTBN2 gene, showed a mild cerebellar atrophy involving the hemispheres and a later onset. In both cases, for the first time, a hyperintense signal of the dentate nuclei was observed.

Introduction
Inherited ataxias are a clinically rare and genetically heterogeneous group of disorders characterized by progressive cerebellar ataxia, incoordination, dysarthria, and difficulty in swallowing, due to pathogenic variants in more than 100 genes identified so far.1–3 Two major groups of ataxia are described: autosomal dominant cerebellar ataxias (also known as spinocerebellar ataxia, SCA) leading to an adult-onset ataxia and autosomal recessive cerebellar ataxias (also known as SCARs). In recent years, it has become clear that the monoallelic or biallelic state of the pathogenic variant is responsible for adult- or infantile-onset cerebellar ataxia.4 Among these, SCA type 5 (SCA5) is a dominant ataxia associated with spectrin beta non-erythrocytic 2 (SPTBN2) gene mutations, characterized by a slowly progressive ataxia with typical adult-onset and global cerebellar atrophy at brain magnetic resonance image (MRI).5–7 The SPTBN2 gene (11q13.2) encodes the b-III spectrin protein, which is primarily expressed in the Purkinje cells of the cerebellum, and it is involved in trafficking and anchoring of crucial
Table 1. Features of the two patients herein described and patients described up to date with early onset SCA5

| Patient          | Sex | SPTBN2 gene mutation | Inheritance | Clinical onset | Developmental delay | Pyramidal signs | Cerebellar findings | Dystonia/ Dyskinesia | Ocular findings | Brain MRI |
|------------------|-----|----------------------|-------------|----------------|---------------------|----------------|---------------------|---------------------|-----------------|-----------|
| This Study       |     |                      |             |                |                     |                |                     |                     |                 |           |
| ID 91618 M      |     | c.185C>G            | de novo     | 5 mo           | +                   | Brisk reflexes | Hypotonia, ataxia  | –                   | Nystagmus, strabismus | 16 mo: severe CA involving both the hemispheres and vermis, with abnormal hyperintense signal of the dentate nuclei. The pons was reduced in volume |
|                  |     | p. Thr62Asn         |             |                |                     |                |                     |                     |                 |           |
|                  |     | het                 |             |                |                     |                |                     |                     |                 |           |
| ID 14020 F      |     | c.1653 + 697_4278+353; p.(Lys551_Gln1426del) g.66463395_66474289del10895 | de novo     | 10 mo          | +                   | Brisk reflexes | Ataxia, tremor     | –                   | Strabismus     | 3 yrs: mild CA involving the hemispheres associated with hyperintense signal of the dentate nuclei. The brainstem and supratentorial brain were normal  |
|                  |     | het                 |             |                |                     |                |                     |                     |                 |           |
| Other studies    |     |                      |             |                |                     |                |                     |                     |                 |           |
| Jacob F         | F   | c.1438C>T          | na          | 12 mo          | +                   | Brisk reflexes | Ataxia, tremor     | –                   | Nystagmus      | 1 yrs: diffuse cerebellar hypoplasia |
| Parolin-Schnekenberg | F | c.1438C>T | de novo | 8 mo | + | - | - | - | Ataxia |
| Mizuno F        | F   | c.1309C>G          | de novo     | 10 mo          | +                   | -               | Ataxia, tremor     | –                   | Nystagmus      | 10 mo and 2 yrs: moderate CA and mild pontine atrophy |
| Nuovo F         | F   | c.1438C>T          | de novo     | 12 mo          | +                   | -               | Ataxia, dysarthria | –                   | Nystagmus      | 1 yrs: global cerebellar hypoplasia |
| Nicita M        | M   | c.479C>T           | de novo     | 5 mo           | +                   | -               | Ataxia             | –                   | Strabismus     | Progressive CA |
| Accogli F       | F   | c.1310G>A          | de novo     | 2 yrs          | +                   | Brisk reflexes | Ataxia, dysarthria | –                   | Nystagmus      | 13 mo: CA (vermis > hemispheres)  |
|                 |     | p. Arg437Gln       |             |                |                     |                |                     |                     |                 | 4 yrs: progressive CA |

(Continued)
neurotransmitter transporters and ion channels to neuronal cell membranes.\textsuperscript{5,8–12} Recently, 11 cases of infantile-onset SCA5 have been reported, all showing global developmental delay, eye movement anomalies, and cerebellar ataxia, carrying either missense or truncating heterozygous mutations in \textit{SPTBN2} gene.\textsuperscript{2,3,7,13–17} In the present study, we describe two new cases of SCA5 with early onset. The first one, carrying a novel heterozygous de novo missense mutation in \textit{SPTBN2} gene, shows a very severe cerebellar atrophy at onset. The latter carries the first de novo intragenic deletion so far reported in \textit{SPTBN2} gene.

**Methods**

The patients’ parents provided written informed consent to the research and to the publication of the results. Study approval by the Ethics committee was provided by the E. Medea Scientific Institute Ethic Committee.

The probands’ DNA were screened using a targeted next-generation sequencing (NGS) approach with a panel of 231 genes. The deletion was identified using ExomeDepth, a powerful bioinformatic tool realized to identify CNVs in exome samples and in NGS data from gene panels. Further details are provided in File S1.

Patients underwent cerebral MRI at 1.5 and 3T. In both cases, multiplanar T1- and T2-weighted images were acquired with age-appropriate TR and TE values. Sedation was required to perform the MRI.

**Results**

The clinical, genetic, and neuroradiological features of the two patients herein described and the 11 patients described up to date with early onset SCA5 are summarized in Table 1. For a detailed description of the two novel patients, see File S1.

**Patient ID 91618**

The patient was the only child (male) of non-consanguineous healthy parents. Perinatal history was normal. Since the first year of life, main developmental milestones appeared delayed and an impairment in social and communication skills was evident. At the age of 16 months, neurological examination showed poor social and communicative interaction, absence of expressive language, axial hypotonia, ataxia, increased deep tendon reflexes, clumsiness, and crawling. Brain MRI at 16 months of age documented a severe cerebellar atrophy involving both the hemispheres and vermis, with abnormal hyperintense signal of the dentate nuclei (Fig. 1A). The pons showed reduced volume. NGS of a panel of 231 genes (see File
S1) showed a novel heterozygous variant c.185C > A (p. Thr62Asn) in SPTBN2 gene. The variant was not present in any of the parents suggesting a de novo origin. The variant was not present in any public database. Predictions of possible pathogenicity were obtained with different software as detailed in File S1. The Thr62 residue is already known to be involved in a mutation, p. Thr62Ile (c.185C > T) 12. The amino acid change falls within the calponin homology domain of b-III spectrin protein (Fig. 2A and B).

**Patient ID 14020**

The patient was the only child (female) of distant consanguineous healthy parents (third-degree cousins). Main developmental milestones appeared delayed. At the age of 20 and 29 months, simple febrile seizures occurred (2–3 min). Repeated EEGs showed during sleep poor organization of background activity without epileptic abnormalities. Brain MRI at 3 years of age showed only mild cerebellar atrophy involving the hemispheres associated with hyperintense signal of the dentate nuclei (Fig. 1B). The brainstem and supratentorial brain were normal. At the age of 37 months, neurological examination showed microcephaly (head circumference 40.9 cm, <3rd centile), poor verbal language (few words), diffuse hypotonia, increased deep tendon reflexes, presence of bilateral Babinski sign, mild dysmetria and tremor, and gait ataxia. A mild developmental delay was documented. Targeted NGS did not lead to any pathogenic variant, but the analysis with ExomeDepth detected a putative heterozygous deletion in SPTBN2 spanning from exon 13 to 20, confirmed by quantitative PCR (qPCR) (data not shown). We subcloned and sequenced the junction fragment from patient genomic DNA (Fig. 2A and B) and we identified two AluSx elements flanking the two breakpoints in intron 12 and 20, which represent the microhomology domains mediating a deletion of 10895bp (g.66463395_66474289del10895) as shown in Figure 3A and B. The deletion was not present in any of the parents suggesting a de novo origin in the patient. Several attempts were made to confirm the deletion at cDNA level starting from RNA extracted from patient’s blood. Due to the lack of SPTBN2 gene expression in blood, no amplification products were obtained. Patient’s parents refused skin biopsy, therefore we can only suppose that the genomic deletion generates an in-frame cDNA deletion from exons 13 to 20, producing a putative protein.

![Figure 1](https://example.com/figure1.png)

**Figure 1.** MRI findings. Patient 1 (row A) at 16 months of age shows a severe vermian and cerebellar atrophy with associated relative pontine atrophy. Patient 2 (row B) at 3 years of age has a milder degree of cerebellar atrophy with a normal pons. In both subjects, dentate nuclei have a hyperintense abnormal signal on T2-weighted sequences (arrowheads).
lacking 875 amino acid residues (p.(551Lys_Gln1426del)) within the spectrin repeats of the SPTBN2 protein (Fig. 3C).

**Discussion**

In recent years, an increasing number of infantile-onset autosomal recessive cerebellar ataxias associated with heterozygous SPTBN2 gene mutations (SCA5) were described. The SPTBN2 protein, expressed in soma and dendrites of cerebellar Purkinje cells, is required for the maintenance of dendritic architecture and for the trafficking and stabilization of several membrane proteins. Mutations in SPTBN2 gene alter dendritic morphology and density and cause changes in Purkinje cells' intrinsic excitability. This reduces sodium currents and causes deficits in glutamatergic neurotransmission. To date, 11 infantile-onset cases of dominant SPTBN2 gene mutations have been reported, four with the same p. Arg480Trp mutation, all showing the common phenotype of developmental delay in early infancy, evolving into intellectual disability and ataxia. Hyperreflexia, dystonia, and eye movement anomalies can be variously present. Herein we describe two novel SCA5 cases with early onset. Clinical findings of both our cases are completely in line with literature. Nevertheless, at brain MRI, the first one showed a striking, very severe cerebellar atrophy at a very young age (16 months) with a global volume reduction of hemispheres and vermis associated with a marked deepening and enlargement of folia sulci and cortical subarachnoid

---

**Figure 2.** Patient’s pedigrees and mutations. Panel (A) represents the patients 91,618 and 14,020 pedigrees. Electropherograms of the mutant and wild-type sequence in patient and in the parents, respectively, are shown. On the right, gel electrophoresis of genomic amplification product in patient 14,020 and control using primer encompassing the putative deleted region. A fragment of approximately 2000 bp is amplified in patient’s DNA only containing the deletion breakpoint. Panel (B) shows a schematic representation of the SPTBN2 protein with the known functional domains, the known mutations (italics character), and the mutations identified in the patients herein described (boxed). The dashed line indicates the deleted region. Acc. N. of the SPTBN2 genomic and protein sequences are NM_006946.2 and NP_008877.1, respectively.
spaces, pons hypoplasia, and a normal-appearing supratentorial brain. The second one showed only a mild cerebellar atrophy. These findings are quite in line with literature reports in which a cerebellar vermis and hemispheric hypoplasia or atrophy of varying degrees with no evidence of cortical involvement are described.²⁻¹⁷ Further, this is the report of the second case of brainstem involvement (pons hypoplasia) so far documented.² In addition, in both our cases, a hyperintense signal of the dentate nuclei was observed, a finding not described in literature up to now associated with SCA5, but found in association with cerebrotendinous xanthomatosis and methotrexate toxicity, both conditions clinically excluded in our patients. From a genetic point of view, the first patient herein reported carried a novel heterozygous de novo missense mutation in \textit{SPTBN2} gene, while the second one harbored the first intragenic deletion of 10895 bp that spans from intron 12 to 20 of the \textit{SPTBN2} gene and leads to a putative protein lacking 875 amino acid within the spectrin repeat region. AluSx sequences were found to flank the breakpoint and likely mediate the deletion event. It is well known that homologous recombination between dispersed Alu sequences can lead to genetic changes, such as duplications, deletions, and translocations, in different disease genes.¹⁸ These sequences of about 300 base pairs share a great level of identity and allow more efficient homologous recombination than sequences with an imperfect identity which would represent an inefficient target.¹⁸,¹⁹ The suggested minimum requirement for favorable homologous recombination is 75% of identity between Alu elements.²⁰,²¹ In our study, we hypothesize that the de novo deletion of 10895 bp in \textit{SPTBN2} gene was generated by an unequal homologous recombination event, due to a misalignment between Alu Sx in intron 12 (5’ deletion boundary) of \textit{SPTBN2} gene and Alu Sx in intron 20 (3’ deletion boundary). Both Alu Sx show 86% sequence identity (91% without gaps) and a microhomology domain of 50 bp. This homology is comparable to that previously reported by Rossetti et al in the factor VIII coagulation gene and that reported by Zhang et al in the mitochondrial acetoacetyl-CoA thiolase (T2) gene.²²,²³

**Figure 3.** Characterization of the deletion breakpoint in Pt 14020. Panel (A) indicates the patient’s genomic DNA sequence encompassing the breakpoint. Panel (B) shows the patient’s genomic DNA sequence alignment between the two intronic regions flanking the breakpoint and containing the AluSx repeats. Panel (C) is a schematic representation of the genomic \textit{SPTBN2} deletion of 10895 bp, which generates a putative in-frame cDNA deletion encompassing exons 13 to 20 of \textit{SPTBN2} gene thereby leading to a putative protein missing 875 aa residues.
Two New Cases of SCA5 With Early Onset

R. Romaniello et al.

studies let us speculate that, also in our case, unequal homologous recombination between Alus was the likely mechanism for this deletion, adding the dominant SCA due to SPTBN2 mutations to the group of the genetic disorders having Alu/Alu recombination as underlying genetic mechanism. Of note, the second patient, carrying the intragenic deletion of SPTBN2 gene, showed a milder clinical (later onset) and neuroradiological phenotype than the patient with the missense mutation.

In conclusion, the authors present two novel cases of infantile-onset SCA associated with a novel SPTBN2 mutation—the first with an early severe cerebellar involvement and the latter with the first intragenic deletion so far reported.

Conflict of Interest

The authors declare no conflict of interest.

Author Contributions

Romaniello performed acquisition of data and funding; drafted the manuscript. Arrigoni performed neuroradiological study and was involved in revising critically the manuscript. Citterio performed molecular data. De Rinaldis performed acquisition of data. Panzeri performed molecular data and was involved in revising critically the manuscript. Bassi was involved in revising critically the manuscript. Citterio was involved in revising critically the manuscript and was involved in revising the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Acknowledgments

The authors wish to thank patients and their families for participating in this work. The work was supported by funds from the Italian Ministry of Health, grant # RC2020 and RC021 (to MTB), RF-NET-2013-02356160 (to RR), 5X MILLE (to RR), and funds from the Fondazione Regionale Lombarda per la Ricerca Biomedica (FRRB) grant # Care4Neurorare (to MTB).

References

1. Bürk K, Zühlke C, König IR, et al. Spinocerebellar ataxia type 5: clinical and molecular genetic features of a German kindred. Neurology 2004;62:327–329.
2. Mizuno T, Kashimada A, Nomura T, et al. Infantile-onset spinocerebellar ataxia type 5 associated with a novel SPTBN2 mutation: a case report. Brain Dev 2019;41:630–633.
3. Accogli A, St-Onge J, Addour-Boudrahem N, et al. Heterozygous missense pathogenic variants within the second spectrin repeat of SPTBN2 lead to infantile-onset cerebellar ataxia. J Child Neurol 2020;35:106–110.
4. Ikeda Y, Dick KA, Weatherspoon MR, et al. Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet 2006;38:184–190.
5. Dick KA, Ikeda Y, Day JW, R anom LP. Spinocerebellar ataxia type 5. Handb Clin Neurol 2012;103:451–459.
6. Elsayed SM, Heller R, Thoenes M, et al. Autosomal dominant SCA5 and autosomal recessive infantile SCA are allelic conditions resulting from SPTBN2 mutations. Eur J Hum Genet 2014;22:286–288.
7. Rea G, Tirupathi S, Williams J, et al. Infantile onset of spinocerebellar ataxia type 5 (SCA-5) in a 6 month old with ataxic cerebral palsy. Cerebellum 2020;19:161–163.
8. Lorenzo DN, Li MG, Mischè SE, et al. Spectrin mutations that cause spinocerebellar ataxia type 5 impair axonal transport and induce neurodegeneration in Drosophila. J Cell Biol 2010;189:143–158.
9. Lise S, Clarkson Y, Perkins E, et al. Recessive mutations in SPTBN2 implicate β-III spectrin in both cognitive and motor development. PLoS Genet 2012;8(12):e1003074. https://doi.org/10.1371/journal.pgen.1003074. Epub 2012 Dec 6.
10. Cho E, Fogel BL. A family with spinocerebellar ataxia type 5 found to have a novel missense mutation within a SPTBN2 spectrin repeat. Cerebellum 2013;12:162–164.
11. Wang Y, Koh K, Miwa M, et al. A Japanese SCA5 family with a novel three-nucleotide in-frame deletion mutation in the SPTBN2 gene: a clinical and genetic study. J Hum Genet 2014;59:569–573.
12. Nicita F, Nardella M, Bellacchio E, et al. Heterozygous missense variants of SPTBN2 are a frequent cause of congenital cerebellar ataxia. Clin Genet 2019;96:169–175.
13. Jacob FD, Ho ES, Martinez-Ojeda M, et al. Case of infantile onset spinocerebellar ataxia type 5. J Child Neurol 2013;28:1292–1295.
14. Parolin Schnekenberg R, Perkins EM, Miller JW, et al. De novo point mutations in patients diagnosed with ataxic cerebral palsy. Brain 2015;138:1817–1832.
15. Al-Muhaizea MA, AlMutairi F, Almass R, et al. A Novel homozygous mutation in SPTBN2 leads to spinocerebellar ataxia in a consanguineous family: report of a new infantile-onset case and brief review of the literature. Cerebellum 2018;17:276–285.
16. Nuovo S, Micalizzi A, D’Arrigo S, et al. Between SCA5 and SCAR14: delineation of the SPTBN2 p. R480W-associated phenotype. Eur J Hum Genet 2018;26:928–929.
17. Zonta A, Brusiino A, Dentelli P, Brusco A. A novel case of congenital spinocerebellar ataxia 5: further support for a specific phenotype associated with the p. (Arg480Trp) variant in SPTBN2. BMJ Case Rep. 2020;13(12):e238108.
implications for copy number variant calling. 
Bioinformatics 2012;28:2747–2754.
19. Deininger PL, Batzer MA. Alu repeats and human disease. 
Mol Genet Metab 1999;67:183–193.
20. Zhang Z, Yagi M, Okizuka Y, et al. Insertion of the 
IL1RAPL1 gene into the duplication junction of the 
dystrophin gene. J Hum Genet 2009;54:466–473.
21. Metzenberg AB, Wurzer G, Huisman TH, Smithies O. 
Homology requirements for unequal crossing over in 
humans. Genetics 1991;128:143–161.
22. Rossetti LC, Goodeve A, Larripa IB, De Brasi CD. 
Homeologous recombination between AluSx-sequences as 
a cause of hemophilia. Hum Mutat 2004;24:440.
23. Zhang G, Fukao T, Sakurai S, et al. Identification of Alu-
mediated, large deletion-spanning exons 2–4 in a patient 
with mitochondrial acetoacetyl-CoA thiolase deficiency. 
Mol Genet Metab 2006;89:222–226.

Supporting Information

Additional supporting information may be found online 
in the Supporting Information section at the end of the 
article.

File S1. Material and Methods and the two Patients 
herein described.